PRESS INFORMATION BUREAU
पत्र सूचना कार्यालय
GOVERNMENT OF INDIA
भारत सरकार

Financial Chronicle, Delhi
Friday 4th July 2014, Page: 6
Width: 8.54 cms, Height: 17.46 cms, a4, Ref: pmin.2014-07-04.31.64

Sun Pharma recalls 200 vials of cancer drug

ZEBA SIDDIQUI
Reuters

MUMBAI: Sun Pharmaceutical Industries is recalling 200 vials of the chemotherapy drug gemcitabine in the United States due to a lack of assurance of sterility, the US food and drug administration said on Thursday.

The drug being recalled was manufactured by Sun Pharma's unit Caraco Pharmaceutical Laboratories at its plant in Gujarat, the FDA said in a post on its website. The voluntary recall was initiated in April and was classified by the FDA as class II, meaning that use of or exposure to the recalled drug may cause temporary or medically reversible adverse health consequences.

This marks Sun Pharma's second drug recall this year. In January, the company started a voluntary recall of about 2,528 bottles of its generic version of diabetes drug Glumetza, after it received a customer complaint that one of the bottles contained tablets of an epilepsy drug.

According to the US health regulator, a class-II recall is given in a situation when the use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

Shares of Sun Pharma closed at Rs 706.35 on the BSE, up 1.79 per cent.

Bottled up

- The voluntary recall was initiated in April and was classified by the FDA as Class II
- The drug being recalled was manufactured by Sun's plant in Gujarat
- In January, it recalled about 2,528 bottles of its generic version of a diabetes drug

Bloomberg

Regulatory